Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05377216

Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation

Prospective cohort study evaluating the electrophysiologic and biochemical effects of stellate ganglion block in patients with ventricular tachycardia.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ventricular Tachycardia Arrhythmias, Cardiac Cardiac Conduction System Disease Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Tachycardia Tachycardia, Ventricular

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location status: Recruiting

Location contact

Timothy Markman, MD

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Planned catheter based VT ablation
  • Age at least 18 years

Exclusion criteria

  • Pregnancy
  • Contraindication to SGB or VT ablation
  • Hypersensitivity of local anesthetic of amide type
  • Hemodynamic instability during the procedure prior to the study protocol

Treatment and study plan

Stellate Ganglion Block

Drug

Left sided percutaneous stellate ganglion block

Primary outcomes

  1. Ventricular Effective Refractory Period

    Time frame: 30 minutes following stellate ganglion block

    Change in Ventricular Effective Refractory Period at 600ms drive train (measured in milliseconds)

Secondary outcomes

  1. Ventricular Arrhythmia Inducibility

    Time frame: 30 minutes following stellate ganglion block

    Induction of monomorphic ventricular arrhythmia (binary outcome) during ventricular programmed stimulation

  2. Neuropeptide Y

    Time frame: 30 minutes following stellate ganglion block

    Change in level of neuropeptide Y from baseline (measured in pg/mL)

Study contacts

Contact information is provided by the study sponsor or research team.

Timothy Markman, MD

CONTACT

[email protected]

267-593-0103

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
May 17, 2022
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.